Estar Technologies Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 30, 2027The maintenance fee for System and method for producing interleukin receptor antagonist (IRA) (US 10,519,196) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for System and method for producing interleukin receptor antagonist (IRA) (US 11,905,311) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 1 fee due Oct 14, 2027The maintenance fee for System and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma (PRP) (US 10,617,812) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,129,930 | System and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma (PRP) In force · USPTO record | In force | USPTO record | |
| US 10,519,196 | System and method for producing interleukin receptor antagonist (IRA) In force · USPTO record | In force | USPTO record | |
| US 10,617,812 | System and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma (PRP) In force · USPTO record | In force | USPTO record | |
| US 11,905,311 | System and method for producing interleukin receptor antagonist (IRA) In force · USPTO record | In force | USPTO record | |
| US 9,962,480 | System and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma (PRP) In force · USPTO record | In force | USPTO record | |
| US 10,167,310 | System and method for producing interleukin receptor antagonist (IRA) In force · USPTO record | In force | USPTO record | |
| US D1,051,378 | Syringe piston In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 7: 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending
Showing 1 to 3 of 3, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/395,751 | Syringe Device Plunger with Axially Extendable Detents and Methods of Using and Processes of Manufacturing the Same | Dec 26, 2023 | Pending |
| 18/684,934 | Method and Apparatus for Preparing Plasma Enriched in IL-1RA | Aug 23, 2022 | Pending |
| 17/916,328 | System and a Method for Obtaining an Improved Plasma Extract | Mar 30, 2021 | Pending |